Merck & Co., Inc. (MRK) Shares Sold by Hutchinson Capital Management CA

Hutchinson Capital Management CA trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 186,709 shares of the company’s stock after selling 2,014 shares during the quarter. Merck & Co., Inc. makes up about 4.8% of Hutchinson Capital Management CA’s portfolio, making the stock its 6th biggest holding. Hutchinson Capital Management CA’s holdings in Merck & Co., Inc. were worth $14,266,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of MRK. WealthPLAN Partners LLC boosted its stake in shares of Merck & Co., Inc. by 1.6% during the 3rd quarter. WealthPLAN Partners LLC now owns 8,377 shares of the company’s stock worth $626,000 after acquiring an additional 135 shares during the period. QCI Asset Management Inc. NY boosted its stake in shares of Merck & Co., Inc. by 4.9% during the 4th quarter. QCI Asset Management Inc. NY now owns 3,178 shares of the company’s stock worth $243,000 after acquiring an additional 149 shares during the period. Atlas Capital Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 11.1% during the 4th quarter. Atlas Capital Advisors LLC now owns 1,528 shares of the company’s stock worth $117,000 after acquiring an additional 153 shares during the period. Traynor Capital Management Inc. boosted its stake in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. Traynor Capital Management Inc. now owns 9,905 shares of the company’s stock worth $756,000 after acquiring an additional 156 shares during the period. Finally, Bfsg LLC boosted its stake in shares of Merck & Co., Inc. by 0.5% during the 4th quarter. Bfsg LLC now owns 33,519 shares of the company’s stock worth $2,561,000 after acquiring an additional 164 shares during the period. Hedge funds and other institutional investors own 72.55% of the company’s stock.

Several analysts recently weighed in on the company. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a report on Friday, January 4th. Cantor Fitzgerald assumed coverage on Merck & Co., Inc. in a report on Friday, February 22nd. They set an “overweight” rating and a $95.00 price target for the company. BMO Capital Markets reissued a “hold” rating on shares of Merck & Co., Inc. in a report on Tuesday, February 19th. Credit Suisse Group set a $86.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, December 13th. Finally, Argus lifted their price target on Merck & Co., Inc. to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 20th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average price target of $77.06.

NYSE:MRK opened at $81.57 on Friday. The company has a market cap of $219.71 billion, a P/E ratio of 18.79, a PEG ratio of 1.99 and a beta of 0.62. The company has a quick ratio of 0.92, a current ratio of 1.17 and a debt-to-equity ratio of 0.74. Merck & Co., Inc. has a 1-year low of $52.83 and a 1-year high of $82.12.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, February 1st. The company reported $1.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.01. The business had revenue of $11 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Merck & Co., Inc. had a return on equity of 36.83% and a net margin of 14.71%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $0.98 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 4.65 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be issued a $0.55 dividend. The ex-dividend date is Thursday, March 14th. This represents a $2.20 annualized dividend and a yield of 2.70%. Merck & Co., Inc.’s dividend payout ratio is presently 50.69%.

In other Merck & Co., Inc. news, CEO Kenneth C. Frazier sold 92,913 shares of Merck & Co., Inc. stock in a transaction on Friday, February 15th. The stock was sold at an average price of $80.03, for a total value of $7,435,827.39. Following the completion of the transaction, the chief executive officer now directly owns 784,863 shares of the company’s stock, valued at approximately $62,812,585.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kenneth C. Frazier sold 53,961 shares of Merck & Co., Inc. stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $80.02, for a total value of $4,317,959.22. Following the completion of the transaction, the chief executive officer now directly owns 733,942 shares of the company’s stock, valued at $58,730,038.84. The disclosure for this sale can be found here. Insiders sold a total of 709,324 shares of company stock valued at $56,162,582 over the last ninety days. Insiders own 0.32% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2019/03/17/merck-co-inc-mrk-shares-sold-by-hutchinson-capital-management-ca.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Recommended Story: Cost of Capital Explained

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply